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Background: This study aims to further evaluate the specificity and selectivity of [18F]FTC-146 and obtain additional
data to support its clinical translation.
Methods: The binding of [19F]FTC-146 to vesicular acetylcholine transporter (VAChT) was evaluated using [3H]vesamicol
and PC12A123.7 cells in an in vitro binding assay. The uptake and kinetics of [18F]FTC-146 in S1R-knockout mice (S1R-KO)
compared to wild-type (WT) littermates was assessed using dynamic positron emission tomography (PET) imaging. Ex
vivo autoradiography and histology were conducted using a separate cohort of S1R-KO/WT mice, and radiation
dosimetry was calculated from WT mouse data (extrapolated for human dosing). Toxicity studies in Sprague–Dawley
rats were performed with a dose equivalent to 250× the anticipated clinical dose of [19F]FTC-146 mass.
Results and discussion: VAChT binding assay results verified that [19F]FTC-146 displays negligible affinity for VAChT
(Ki = 450 ± 80 nM) compared to S1R. PET images demonstrated significantly higher tracer uptake in WT vs. S1R-KO
brain (4.57 ± 1.07 vs. 1.34 ± 0.4 %ID/g at 20–25 min, n = 4, p < 0.05). In S1R-KO mice, it was shown that rapid brain
uptake and clearance 10 min post-injection, which are consistent with previous S1R-blocking studies in mice.
Three- to fourfold higher tracer uptake was observed in WT relative to S1R-KO mouse brains by ex vivo autoradiography.
S1R staining coincided well with the autoradiographic data in all examined brain regions (r2 = 0.85–0.95). Biodistribution
results further demonstrated high [18F]FTC-146 accumulation in WT relative to KO mouse brain and provided
quantitative information concerning tracer uptake in S1R-rich organs (e.g., heart, lung, pancreas) for WT mice vs.
age-matched S1R-KO mice. The maximum allowed dose per scan in humans as extrapolated from mouse dosimetry was
33.19 mCi (1228.03 MBq). No significant toxicity was observed even at a 250X dose of the maximum carrier mass
[19F]FTC-146 expected to be injected for human studies.
Conclusions: Together, these data indicate that [18F]FTC-146 binds specifically to S1Rs and is a highly promising
radiotracer ready for clinical translation to investigate S1R-related diseases.
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Based on sigma receptor (SR) binding studies, two sub-
types have been characterized: sigma-1 receptors (S1Rs)
and sigma-2 receptors (S2Rs) [1]. S1Rs are involved in a
large range of basic biological processes and multiple
chronic disease states, including neuropathic pain, depres-
sion, Alzheimer’s disease (AD), and schizophrenia [2–5].
S1R is a 26.2 kDa ligand-gated membrane chaperone pro-
tein that is Ca2+-sensitive, residing in the mitochondria-
associated endoplasmic reticulum (ER) membrane, and is
highly conserved across mammalian species [6]. Due to its
subcellular localization, S1R is proposed to function as an
interorganelle-signaling modulator [7]. Although some
S1R agonists have showed efficacy as therapeutic agents in
various neuropsychiatric diseases [8], vascular diseases [9],
and cancer [10], the exact biochemical role of S1Rs in
these disease states is yet to be fully elucidated.
During the last decade, a variety of small molecules have
been developed for S1R-PET imaging [11]. Among those
ligands, most human studies have been performed with
[11C]SA4503 (S1R Ki = 4.6 nM) [12]. Although
[11C]SA4503 has provided valuable information about S1R
distribution in healthy controls, AD, and Parkinson’s dis-
ease patients [13], this radiotracer also displays significant
affinity for S2R and the vesicular acetylcholine transporters
(VAChT) (i.e., S2R Ki = 63 nM [9], VAChT Ki = 50 nM [14];
S2R/S1R = 13.6; VAChT/S1R = 10.9), confounding inter-
pretation of its PET imaging data with respect to S1R.
There were also other promising S1R radioligands, such as
[18F]FPS [15] and [18F]fluspidine [16]. However, the former
has only ~30-fold selectively for S1R compared to S2R re-
ceptors (Table 1) [17, 18], and neither of these imaging
agents have been evaluated in S1R-KO mice.
Ideally, a radiotracer should possess high specificity and
selectivity for the target of interest in order to obtain spe-
cific and highly quantifiable imaging data. The specific
and selective imaging of S1Rs with PET may provide crit-
ical insight about the in vivo distribution, expression
levels, and functional role of these receptors in normal
and aberrant physiology. We previously reported the syn-
thesis and initial evaluation of an S1R antagonistTable 1 Comparison of sigma-1 receptor ligand binding affinities to
FTC-146 (−)-Vesamicol SN-56
S1R K1 (nM) 0.0025 74 [24] 0.56
S2R K1 (nM) 364 364 [24] >1000
VAChT K1 (nM) 450 20 140radioligand, [18F]FTC-146 [19, 20]. In those studies, we
showed that this tracer has picomolar affinity (S1R
Ki = 2.5 pM) and a >1000-fold selectivity for S1R over
S2R. Mouse PET imaging corroborated the specific
binding of [18F]FTC-146 to S1Rs in vivo through
blocking studies with known S1R ligands. Moreover,
we observed specific uptake of [18F]FTC-146 in S1R-rich
regions of rat and in non-human primate brain. While all
of these data are encouraging, the affinity of our tracer for
VAChT, a common off-target binding site for S1R ligands,
was not evaluated. Additionally, while we have shown that
[19F]FTC-146 does not display significant affinity for 59
other central nervous system (CNS) targets by in vitro
binding studies, the absolute specificity and selectivity of
this tracer for S1Rs in vivo has not been determined.
In the current study, we set out to determine the specifi-
city and selectivity of [18F]FTC-146 for S1Rs, validating its
use for specific PET imaging of S1R levels. Furthermore,
we sought to accumulate other information, including
dosimetry and toxicology, required for the translation of
this PET tracer to the clinic. The amalgamation of our
current findings regarding the application of [18F]FTC-146
to WT and age-matched S1R-KO mice with our previous
findings provides definitive evidence that our tracer is
highly specific and selective for S1Rs, both in vitro and
in vivo. To the best of our knowledge, this is the first study
to evaluate a S1R radiotracer in S1R-KO mice and to dem-
onstrate a correlation between tracer accumulation and
S1R immunostaining in brain.
Methods
General
Unless otherwise stated, chemicals were purchased from
commercial sources and used without further purification.
BD1047 for mice studies was purchased from Sigma Al-
drich. [19F]FTC-146 (99.1 % chemical purity) reference
compound was provided by Albany Molecular Research
Inc. (Albany, NY). Radiochemistry and semi-preparative
high performance liquid chromatography (HPLC) was
performed using a TRACERlab FX-FN module (GE
Healthcare) with an ancillary HPLC pump (Dionex P680)S1R, S2R, and VAChT
SA4503 FPS Fluspidine
4.6 4.3 [17] 0.59 [18]
63 142 [17] 708 [18]
50 N/A 1400 [18]
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performed on a quaternary pump (Agilent 1200 series)
equipped with an autosampler, a photodiode array UV de-
tector, and a model 105S single-channel radiation detector
(Carroll & Ramsey Associates). Radiotracer doses for ani-
mal studies were measured using a dose calibrator (Capin-
tec, CRC-15 PET). Positron emission tomography/
computed tomography (PET/CT) imaging of mice was per-
formed using microPET/CT hybrid scanner (Siemens
Inveon). All PET data were reconstructed using a 3-
dimensional ordered subsets expectation maximization al-
gorithm (16 subsets, 4 iterations) with scatter and dead time
correction, and a matrix size of 128 × 128 × 159. Attenu-
ation correction was applied to dataset from CT image.
VAChT binding affinity
In vitro binding assays for VAChT were conducted with
human VAChT stably expressed in PC12A123.7 cells at
about 50 pmol/mg of crude extract. No significant
amounts of S1Rs and S2Rs were present. The VAChT
radioligand used was 5 nM (−)-[3H]vesamicol (24.3 Ci/
mmol; 899 GBq/mmol), and the assay was conducted at
final concentrations of 10−11 M to 10−4 or 10−5 M of S1R-
targeting compounds [21]. Nonspecific binding was deter-
mined with 5 μM (±)-vesamicol. Unlabeled (−)-vesamicol
was used as an external standard (Ki ~ 15 nM) and the
sealed mixtures were allowed to equilibrate at 23 °C for
20 h. Duplicate data were averaged and fitted by regres-
sion of a rectangular hyperbola to estimate the Ki values
of the novel compounds (Additional file 1: Figure S1).
Animals
Oprs1 mutant (+/−) OprsGt (IRESBetageo) 33Lex litters on
a C57BL/6 J × 129 s/SvEv mixed background were purchased
from the Mutant Mouse Regional Resource Center, UC
Davis, CA, from which homozygous WT (Sigma-1 receptor
+/+) and S1R-KO (Sigma-1 receptor −/−) mice were ob-
tained through in-house breeding. All mice were maintained
on a 4 % fat diet (Harland Teklad, 8604 M/R) and subjected
to standard light cycles (12 h/12 h light–dark). Stanford Uni-
versity Institutional Animal Care and Use Committee ap-
proved all experimental procedures involving animals.
Genotyping
Mice were bred onsite, and tail samples were collected
from mice litters and sent to Transnetyx Inc to determine
genotype (Cordova, TN, USA). Mice were always re-
genotyped at the conclusion of each experiment.
Radiochemistry
[18F]FTC-146 was synthesized via aliphatic nucleophilic
substitution (18F/tosylate exchange) using TRACERlab
FX-FN as previously described [19]. Briefly, tosylate pre-
cursor solution (2 mg in 1 mL anhydrous DMSO) wasadded into azeotropically dried 18F/K222/K2CO3 com-
plex, heated to 150 °C for 15 min, and then the crude
product was purified on semi-prep HPLC. The
[18F]FTC-146 HPLC fraction was formulated in saline
containing no more than 10 % ethanol.
Small animal magnetic resonance imaging (MRI)
Mice were scanned with a dedicated small animal 7 Tesla
Varian Magnex Scientific MR scanner with custom-designed
pulse sequences and radiofrequency (RF) coils using stand-
ard methods. The scanner consisted of a superconducting
magnet (Magnex Scientific) with 7.0 Tesla field strength, a
gradient insert (Resonance Research, Inc.) with clear bore
size of 9 cm (770 mT/m, 2500 T/m/s), a General Electric
(GE) console, and Copley 266 amplifiers. For each MR
scan, mice were anesthetized using isoflurane gas (2.0–
3.0 % for induction and 1.5–2.5 % for maintenance). Body
temperature was continually monitored and maintained
within the normal range using a temperature sensor. Res-
piration rate and oxygen saturation were also monitored
throughout scan. Coronal brain images were acquired
using T2-weighted fast spin echo sequences (TE/TR
58.5 ms/4000 ms) using 9 NEX, a 256 × 256 matrix, 3 cm
field of view, slice thickness of 500 μm, and a total imaging
time of 19 min. Mouse brain MRI data was used to provide
an anatomical reference frame for PET/CT imaging.
Small animal PET/CT imaging
Mice were anesthetized using isoflurane inhalation
(2.0–3.0 % for induction and 1.5–2.5 % for mainten-
ance, isofluorane in oxygen at a flow rate of 2 L/min).
Following tail vein cannulation, each catheterized
mouse was placed in a custom-made 4 × 4 mouse bed.
All mice were kept warm using an infrared warming
pad (Kent Scientific) placed under and around the bed
while under isoflurane anesthesia in the microPET/CT
scanner (pixel size 200 μm). A 5-min CT scan was
performed just prior to each PET scan. Acquisition of
dynamic PET data (4 × 15 s, 4 × 60 s, 11 × 300 s) for
WT (n = 4) and S1R-KO (n = 4) mice commenced just
prior to intravenous administration of [18F]FTC-146
(45–130 μCi; 1.67–4.81 MBq), followed by 50 μL ster-
ile heparinized saline to flush cannula, and yielded a
total of 19 frames over 60 min. Blocking studies in-
volved pre-treating WT (n = 4) and S1R-KO (n = 4)
mice with BD1047 (1 mg/kg, Sigma Aldrich) 10 min
prior to radioligand administration. PET, CT, and
MR images were imported into Inveon Research
Workspace 4.0 (Siemens) and co-registered using the
automatic affine registration. Tracer activity over
time was measured in regions of interest in the PET
image (mean activity in the region) by using each
brain MR image as an anatomical guide (Additional
file 2: Figure S2). Regions of interest were selected
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cluded previously reported S1R-rich brain structures
(i.e., caudate putamen, cerebellum, cortex, and hippo-
campus) [22].
Ex vivo biodistribution and stability
WT (n = 5) and S1R-KO mice (n = 5) were administered
[18F]FTC-146 (60–90 μCi; 2.2-3.3 MBq) via tail vein injec-
tion. Blood samples were collected via cardiac puncture
25 min following tracer administration, and each mouse
was perfused with saline (10–20 mL) prior to sacrificing
and removing organs of interest (i.e., brain, heart, kidney,
liver, lung, muscle, pancreas, small intestine, spleen, stom-
ach). The radioactivity in weighed organs was assessed in
automated gamma counter (Cobra II; Packard) and decay
corrected to the time of radiotracer injection using diluted
aliquots of the initial administered dose as standards. An-
other set of WT mice (n = 4) were used to evaluate the
ex vivo stability of [18F]FTC-146 in brain, liver, kidney, small
intestine, and stomach homogenates at 25 min after tracer
administration (using previously reported methods [20]).
Ex vivo autoradiography
Coronal brain sections from WT (n = 3), heterozygous (n
= 1), and S1R-KO (n = 4) mice were harvested 30 min
post-injection of [18F]FTC-146 (200–300 μCi; 7.4–
11.1 MBq). After perfusing each mouse with saline (15–
20 mL), the brain was removed and divided into two sagit-
tal halves. Half of each brain was embedded in optimal cut-
ting temperature (OCT) compound (Tissue-Tek) and
frozen on dry ice for ex vivo autoradiography, while the
other half was fixed in 4 % paraformaldehyde (PFA) for im-
munohistochemistry. Muscle samples from front leg,
known to contain negligible levels of S1R, were also dis-
sected and embedded alongside corresponding brain tissue
to be used as an internal reference region for each mouse
in order to normalize ex vivo autoradiography data. Cor-
onal brain and muscle sections (20 μm thick) were cut
using a cryostat microtome HM500 (Microm), mounted
on microscope slides (Fisherbrand SuperfrostTM Plus
Microscope Slides), air-dried for at least 10 min, and then
exposed to 18F-sensitive storage phosphor screens (Perkin
Elmer) overnight at −20 °C. Each phosphor screen was
scanned using a Typhoon 9410 Variable Mode Imager
(Amersham Biosciences) and image data were visualized
and quantified using ImageJ (Image processing and analysis
software in Java, version 1.45 s). Anatomy of brain sections
was confirmed by Nissl staining (cresyl violet acetate;
Sigma Aldrich) using standard techniques.
Immunohistochemistry
S1R immunostaining was performed using free-floating
40-μm-thick coronal brain sections from WT (n = 3) and
S1R-KO (n = 4) mice. Sections were incubated in a 1 %H2O2, 50 % TBS (pH = 7.4)/MeOH solution for 30 min to
quench the endogenous peroxidase activity and subse-
quently blocked with 10 % normal goat serum (NGS; Vec-
tor Laboratories) in TBST (1 % Triton X-100, Sigma
Aldrich) for 1 h to reduce nonspecific staining and to
permeabilize the tissue. Sections were then incubated with
S1R specific primary antibody (1:400, [23]) containing 5 %
NGS and TBST overnight at room temperature. Following
this, the sections were incubated with biotinylated anti-
rabbit secondary antibody 1:200 (Vector Laboratories) in
5 % NGS and TBST for 1 h at room temperature and then
with avidin-biotin complex (diluted 1:1000 in TBS, Vector
Laboratories) for 90 min at room temperature. Finally,
sections were incubated with 3,3′-diaminobenzidine
(DAB; Sigma Aldrich) for 10 min, mounted on slides,
dehydrated, and then cover-slipped with Permount
(Sigma Aldrich). Images of the immunostained sec-
tions were taken with a Nanozoomer (Hamamatsu),
and images were quantified using ImageJ.
Dosimetry
Mice (WT, female n = 3; male n = 3) were imaged for 2 h
using Inveon PET/CT following a high-resolution CT
(pixel size 103.2 μm). An additional two 10-min static
PET/CT scans at 4 and 6 h were performed on these mice
that were allowed to be awake between scans. ROIs were
drawn over the brain, thyroid, heart, liver, lung, gallbladder,
spleen, kidneys, urinary bladder, bone, muscle, and testicle/
uterus of the mice by using the image analysis software
IRW (Siemens) with the help of the CT images. The %ID/g
associated with each ROI was extracted and underwent an
animal-human biokinetic extrapolation using the percent
kg/g method. Source organ residence times were calculated
using a standard quantitation platform organ level internal
dose assessment (OLINDA) utilizing a bi-exponential
model without bladder voidance. The projected human ra-
diation doses were then computed for male and female
phantoms using the source organ residence times.
Toxicity of [19F]FTC-146
This study was conducted by SoBran Bioscience
(Baltimore, MD). It consisted of one test article treat-
ment group of ten male and ten female Sprague–Dawley
rats dosed with [19F]FTC-146 at 0.069 mg/kg, equivalent
to 250× the anticipated clinical dose mass. An additional
group of ten males and ten females received the vehicle,
10 % ethanol in sterile saline, and served as the control.
All rats received a dose volume of 5 mL/kg. The rats
were dosed intravenously once on study day 1. Five male
and five female rats from each group were bled on study
day 3 and the remaining rats were bled on study day 15.
All animals were euthanized and necropsied following
blood collection. Parameters evaluated for test article ef-
fect included survival, clinical observations, body weight,
Fig. 1 a Representative coronal PET/MR brain images of baseline
WT/S1R-KO and blocking WT groups (n = 4 per group; blocking with
BD1047 at 1 mg/kg). ctx = cortex; cp = caudate putamen;
hc = hippocampus; cer = cerebellum. b Time activity curves
depicting accumulation of [18F]FTC-146 in whole brain over time. We
observed significantly higher brain uptake in baseline WT mice
compared to S1R-KO mice at all time points during 60 min PET scan
(P< 0.05). The kinetics of [18F]FTC-146 in WT blocking, S1R-KO baseline,
and S1R-KO blocking studies all exhibited similar kinetics: i.e., the tracer
quickly entered and cleared from the brain within 10 min post-injection
Shen et al. EJNMMI Research  (2015) 5:49 Page 5 of 10body weight gain, clinical pathology, gross pathology,
organ weights, and microscopic pathology.
Statistical analyses
Results are presented as mean value ± standard deviation
(STDV) for radiochemistry, PET/CT imaging, ex vivo
biodistribution and stability and dosimetry studies; mean
value ± standard error of the mean (SEM) is shown for
ex vivo autoradiography and immunohistochemistry
studies. Unpaired t tests (one tail) were used to compare
PET/autoradiography/IHC data from WT with S1R-KO
mice. Correlations between autoradiography mean signal
intensity and S1R staining were determined by Pearson
correlation test. All statistical analyses were performed
using Microsoft Excel (version 14.0.7) or GraphPad
Prism software (version 6.0c; GraphPad). A p value of
less than 0.05 was considered as statistically significant.
Results
Radiochemistry
[18F]FTC-146 was obtained with radiochemical yield of
2.8 ± 1.2 % and specific radioactivity of 4.1 ± 2.1 Ci/μmol
(151.7 ± 77.7 GBq/μmol). Both radiochemical and chem-
ical purities were >99 %. All radiochemical yields and
specific radioactivities were decay corrected to end of
bombardment (n = 11).
VAChT binding affinity
Competitive inhibition experiments using (−)-[3H]vesa-
micol were performed to estimate affinities of FTC-146
and SN-56 for VAChT (Table 1). Unlabeled (−)-vesamicol
was used as an internal standard and was found to
have an affinity of Ki = 13 ± 1 nM for VAChT, which
is within the typical range known for this compound
[24]. In the same assay, FTC-146 was shown to have
an affinity of Ki = 450 ± 80 nM for VAChT, which is
180,000-fold less affinity than its picomolar affinity
for S1R [19]. The non-fluorinated S1R compound,
SN-56, was found to have an affinity of Ki = 140 ± 18 nM
for VAChT in the same assay.
PET/CT/MR imaging
In vivo [18F]FTC-146 uptake and pharmacokinetics in
WT and S1R-KO mice were assessed by dynamic PET/
CT imaging. Representative whole brain PET/MR im-
ages and time activity curves for both WT and S1R-KO
mice are shown in Fig. 1. These graphs demonstrated
that [18F]FTC-146 entered the brain of both WT and
S1R-KO mice rapidly with peak uptake occurring
within 3 min post-injection (6.46 ± 1.33 %ID/g for
WT; 5.07 ± 0.88 %ID/g for S1R-KO, n = 4), with
much faster washout observed in S1R-KO mice com-
pared to WT mice (76 % reduction vs. 37 % reduction at
30 min post-injection). Overall, we found significantlyhigher accumulation of [18F]FTC-146 in whole brain
of WT mice compared to S1R-KO mice (whole brain:
4.57 ± 1.07 vs. 1.34 ± 0.44 %ID/g at 20 min, n = 4, p < 0.05).
Similarly, in several S1R-rich brain regions (Fig. 2), we ob-
served marked accumulation of [18F]FTC-146 in WT
baseline studies, while S1R-KO brains, as well as WT and
S1R-KO brains following receptor blocking with a known
S1R antagonist (BD-1047), showed similarly rapid washout
of tracer.
Ex vivo biodistribution and stability
To quantitatively determine the uptake of [18F]FTC-146
in WT versus S1R-KO mice, we performed ex vivo bio-
distribution studies 25 min post-injection of tracer
(Fig. 3). Similar to our PET imaging results, we observed
significantly higher uptake of [18F]FTC-146 in the brain
of WT mice compared to S1R-KOs (biodistribution:
4.85 ± 0.59 vs. 0.86 ± 0.28 %ID/g, p < 0.05; PET: 4.57 ±
1.07 vs. 1.34 ± 0.4 %ID/g at 25 min, p < 0.05). In
addition, we observed significantly greater [18F]FTC-
146 uptake in peripheral organs known to contain
moderate to high levels of S1Rs [6, 25], including the
Fig. 2 Time activity curves depicting accumulation of [18F]FTC-146 in a cortex, b caudate putamen, c hippocampus, and d cerebellum for
baseline and blocking studies in WT and S1R-KO mice (n = 4 per group; blocked with BD1047 at 1 mg/kg)
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(2.63 ± 0.55 vs. 0.90 ± 0.17 %ID/g, p < 0.05), pancreas
(11.32 ± 1.98 vs. 5.46 ± 1.08 %ID/g, p < 0.05), spleen
(9.37 ± 2.06 vs. 5.00 ± 1.33 %ID/g, p < 0.05), and kidney
(11.40 ± 1.58 vs. 7.78 ± 1.74 %ID/g, p < 0.05). However,
we did not find significant differences between WT andFig. 3 Ex vivo biodistribution of [18F]FTC-146 in mice 25 min after
injection of radioligand (n = 5, p < 0.05)S1R-KO [18F]FTC-146 uptake in muscle, whole blood,
small intestine, or stomach, in which muscle and blood
contain very low if any S1Rs; and small intestine and
stomach contain notable levels of S1Rs [26, 27]. Lastly,
our ex vivo [18F]FTC-146 stability results showed 100 %
intact [18F]FTC-146 in the brain, but different levels of
degradation in liver (29 % intact), stomach (45 % intact),
small intestine (55 % intact), and kidney (34 % intact)
(Additional file 3: Table S1).
Ex vivo autoradiography
The distribution of [18F]FTC-146 in mouse brain was
further evaluated by high-resolution ex vivo autoradi-
ography. In WT mice, [18F]FTC-146 mainly accumu-
lated in the cortex, cerebellum, caudate putamen,
and hippocampus. Similar to in vivo PET results,
there was significantly less [18F]FTC-146 uptake in
the brain of S1R-KO mice compared to WT mice.
The level of tracer accumulation in all regions of
S1R-KO mouse brain was comparable with that ob-
served in muscle. The normalized autoradiography
signals in all WT brain regions analyzed (WT vs.
S1R-KO) are as follows: 3.53 ± 0.07 vs. 0.91 ± 0.10 in
cortex; 3.54 ± 0.39 vs. 0.97 ± 0.03 in caudate putamen;
3.44 ± 0.33 vs. 1.03 ± 0.08 in hippocampus; 3.47 ± 0.33 vs.
1.01 ± 0.06 in cerebellum (n = 3 for WT, n = 4 for S1R-KO;
p < 0.05, Fig. 4).
Fig. 4 Ex vivo autoradiography of S1R-KO and WT mice (25 min P.I.). a Top row contains representative autoradiography images of [18F]FTC-146
from coronal sections throughout the brain of WT & S1R-KO (KO) mice. Second row shows Nissl staining of same sections used for autoradiography
(for anatomical comparison). b Mean signal intensity for specific brain regions normalized to muscle for WT and KO mice. We observed three- to
fourfold higher uptake of [18F]FTC-146 in all analyzed brain regions for WT mice compared to KO mice (n = 3 WT; n = 4 S1R-KO)
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In order to evaluate the relationship between [18F]FTC-
146 autoradiography signal and levels of S1R staining,
we conducted S1R-immunohistochemistry with brain
tissue from the same mice used for autoradiography
studies. Results from these studies revealed high levels
of S1R staining in brain tissue from WT mice, especially
in the cortex, caudate putamen, hippocampus, and cere-
bellum. S1R-KO mouse brain sections were found to be
devoid of S1R staining. Mean pixel intensities for WT vs.
S1R-KO brain sections were found to be 7.99 ± 0.16 vs.
1.53 ± 0.03 for cortex; 5.29 ± 0.18 vs. 1.57 ± 0.07 for
caudate putamen; 4.96 ± 0.50 vs. 1.39 ± 0.02 for hippo-
campus; and 6.82 ± 0.52 vs. 1.65 ± 0.04 for cerebellum
(n = 3 for WT, n = 4 for S1R-KO, p < 0.05, Fig. 5).
Autoradiography and S1R staining were also performed on
brain tissue from a S1R-KO heterozygous (+/−) mouse in
order to investigate correlation between S1R staining levels
and autoradiography signal. A strong correlation between
S1R expression level and autoradiography signal was found
in the cerebellum (r2 = 0.94) and cortex (r2 = 0.95), whereas
there was a moderate to strong correlation in the hippo-
campus (r2 = 0.85) and caudate putamen (r2 = 0.86) (Fig. 6).
Dosimetry
A representative whole body 3D image [18F]FTC-146 in
WT mice and region of interest is presented in Additional
file 4: Figure S3. The estimated radiation doses as extractedfrom mice were 0.032 rem/mCi (1.18 rem/MBq) in fe-
males and 0.011 rem/mCi (0.41 rem/MBq) in males.
The estimated absorbed radiation doses to human tar-
get organs are presented in Additional file 5: Table S2.
Highest radiation doses were found in the spleen, urin-
ary bladder, and bone. The dose-limiting organ was the
bone (osteogenic cells), since bone is considered a crit-
ical organ for active blood-formation with a limit of
3 rem/single dose (5 rem/yearly). The single/yearly dose
limit to human female or male was estimated to 33.19 mCi
(1228.03 MBq) single dose/55.31 mCi (2046.47 MBq)
yearly dose and 50.34 mCi (1862.42 MBq) single dose/
83.89 mCi (3104.03 MBq) yearly dose, respectively.
Toxicity of [19F]FTC-146
Following treatment with FTC-146, animals remained
bright, alert, and responsive at all times and did not ex-
hibit signs of toxicity during the conduct of the study.
No treatment-related differences were noted in mean
body weights, clinical chemistry, hematology, or coagula-
tion parameters. In addition, no treatment-related effects
were observed for organ weights or in gross and micro-
scopic pathology. A brief summary of this data is pre-
sented in Additional file 6: Table S3.
Discussion
S1Rs have received much attention from the molecular
imaging community due to their involvement in a
Fig. 5 a Representative coronal S1R-stained WT and S1R-KO mouse brain sections. Images were all acquired using a nanozoomer with the same
settings and are all shown on the same scale (40× magnified). b Staining differences between WT and S1R-KO brain sections were calculated by
comparing pixel intensities of regions of interest after normalizing the sections to their background reading. (n = 3 WT; n = 4 S1R-KO)
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Highly specific and selective S1R radioligands are critical
to understanding the in vivo role of this receptor and
how its levels change over time in these disease states.
Such radioligands could enable noninvasive detectionFig. 6 Correlation between autoradiography signal and S1R immunostainin
S1R-KO (−/−), heterozygous (+/−), and WT mice (n = 3 WT; n = 1 heterozygand staging of diseases, e.g., AD and chronic pain, as
well as monitoring novel S1R-related therapeutics.
The aim of the current work was to further investigate
the selectivity, specificity, dosimetry, and safety of a prom-
ising, previously reported S1R radioligand, [18F]FTC-146.g for the cerebellum, cortex, caudate putamen, and hippocampus of
ous; n = 4 S1R-KO)
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in vivo images of S1R density and to provide a foundation
to translate [18F]FTC-146 for clinical imaging.
The present work provided definitive evidence con-
cerning the high specificity and selectivity of [18F]FTC-
146 for S1Rs, both in vitro and in vivo. Specifically, we
found that [19F]FTC-146 has only negligible in vitro af-
finity for VAChT compared to its picomolar S1R affinity
(i.e., VAChT Ki = 450 nM, S1R Ki = 0.0025 nM) and that
there is only negligible [18F]FTC-146 brain uptake in
S1R-KO mice compared to age-matched WTs. We also
showed that [18F]FTC-146 brain autoradiography results
for WT and S1R-KO mice corresponded well with PET
imaging results and that there is a good correlation
between [18F]FTC-146 accumulation and extent of S1R
immunostaining in all brain regions investigated (i.e., caud-
ate putamen, cerebellum, cortex, and hippocampus).
This S1R-KO study also allowed to us to capture a
global perspective of FTC-146 binding affinity to all
brain targets including emopamil-binding protein (EBP),
which is known to display significant sequence hom-
ology to the S1R protein and is thus another potential
off-target binding site for S1R ligands [30]. For example,
SA4503 has been reported to display low nanomolar
affinity for EBP (Ki = 1.7 nM). Since we observed negli-
gible uptake of [18F]FTC-146 in S1R-KO mice compared
to age-matched WTs, we considered this to be good
validation of this tracer’s high selectivity/specificity for
S1R in vivo, and confirmation that this tracer does not
interact significantly with EBP in vivo.
Biodistribution data also illustrated significantly higher
[18F]FTC-146 uptake in the brain and most S1R-rich
peripheral organs in WTs compared with S1R-KO mice
(between two- and fivefold). However, we did not ob-
serve a significant difference in the liver, stomach, or
small intestine uptake, which have all previously been re-
ported as S1R-rich organs [27]. This is likely due to the
presence of radioactive metabolites produced in the liver
and then subsequently passed to the stomach and small
intestine (see Additional file 3: Table S1). In addition,
there is a higher [18F]FTC-146 concentration in blood
from S1R-KO mice compared to WTs, which is likely
due to the lower amount of tracer binding in these mice
(which lack S1Rs) leading to more tracer being available
to circulate in blood. Finally, from mouse radiation dos-
imetry, we estimate that bone would be the rate-limiting
organ with an estimated absorbed radiation dose in
human males of 0.090 rem/mCi. Defluorination was
observed in mice in previous study [19]. However
[18F]FTC-146 showed more chemical stability when it
was studied in larger species, such as rats and squirrel
monkeys [20]. Therefore, we can assume that the bone
uptake may be even lower once a full human dosimetry
study has been carried out. Lastly, [19F]FTC-146 toxicitystudy in Sprague–Dawley rats proves the amount of
[19F]FTC-146 included in a radiotracer dose likely is safe
for human administration.
To the best of our knowledge, this is the first study to
evaluate a S1R radiotracer in S1R-KO mice and to dem-
onstrate a correlation between tracer uptake and S1R
immunostaining in different mouse brain regions. These
additional findings provide critical information to under-
stand the selectivity/specificity of a radiotracer for its de-
sired target and for determining what the PET/
autoradiography imaging signal actually represents.Conclusions
The results achieved from this study, together with the
fact that [18F]FTC-146 has the highest in vitro affinity
and selectivity for S1R over S2R of any published radioli-
gand to date, illustrate the potential of [18F]FTC-146 for
serving as a clinically useful, highly accurate imaging
tool for investigating S1Rs in health and disease. We are
currently evaluating the utility of [18F]FTC-146 for de-
tecting and monitoring S1R-related neurological disor-
ders, including chronic pain and AD. Additionally, based
on these encouraging findings, we are now moving for-
ward with an exploratory Investigational New Drug ap-
plication, utilizing the dosimetry estimation in WT mice
and evaluation of tracer toxicity we have performed, for
approval from the U.S. Food and Drug Administration
to allow us to perform our first-in-human tracer bio-
distribution and dosimetry studies with clinical-grade
[18F]FTC-146.Ethical approval
Stanford University Institutional Animal Care and Use
Committee approved all experimental procedures in-
volving animals.Informed consent
This article does not contain any studies with human
participants performed by any of the authors.Additional files
Additional file 1: Figure S1. FTC-146, SN-56 and Vesamicol binding
affinity to VAChT. (DOC 171 kb)
Additional file 2: Figure S2. Representative MR images showing how
regions of interest (ROIs) were drawn for 1 = cortex; 2 = caudate
putamen; 3 = hippocampus, 4 = cerebellum during PET/MR image
analysis. Whole brain ROIs were drawn using the skull from the CT
image as a guide. (DOC 573 kb)
Additional file 3: Table S1. Ex vivo stability of [18F]FTC-146 in WT
mouse (n = 4). (DOC 29 kb)
Additional file 4: Figure S3. Representative microPET/CT 3D summed
image from 30–45 min post injection of [18F]FTC-146 (Left). Region of interest
(ROI) drawn with the help of CT anatomical images (Right). (DOC 505 kb)
Shen et al. EJNMMI Research  (2015) 5:49 Page 10 of 10Additional file 5: Table S2. Estimated human radiation doses
extrapolated from mouse data. (DOC 40 kb)
Additional file 6: Table S3. Summary of [19F]FTC-146 toxicity study in
rats. (DOC 34 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FTC conceived the idea for, and initiated this project. BS and MLJ designed
and coordinated experiments and prepared the manuscript. CRM synthesized
and provided precursor and standard for the PET probe. BS and NCA prepared
the radiolabeled PET probe. KK and SMP carried out binding assays; CL, SC, and
SS performed the animal breeding. BS, MLJ, LA, AS, and SC performed PET
study and ex vivo biodistribution; MLJ, LA, MZ, and CL performed ex vivo
autoradiography and immunohistochemistry; MLJ and BS analyzed the PET,
autoradiography and immunohistochemistry data and performed the statistical
analyses; MP performed dosimetry study; FTC, AS, and SSG provided guidance
and helped troubleshoot various aspects of this project. All authors read and
approved the final manuscript.
Acknowledgements
This funding was supported in part by the NCI ICMIC P50 CA114747 (SSG);
NIDA R01 DA023205 (CRM); NIGMS P20 GM104932; and Stanford University
Department of Radiology Startup Funding NIH 1S10 OD018130 (FTC). We
would also like to thank Dr. Timur Mavlyutov and Dr. Arnold E. Ruoho for
providing S1R specific antibody, the MIPS Cyclotron & Radiochemistry
Facility, and Small Animal Imaging Facility for their support.
Funding
This study was supported in part by the NCI ICMIC P50 CA114747 (SSG);
NIDA R01 DA023205 (CRM); NIGMS P20 GM104932; and Stanford University
Department of Radiology Startup Funding NIH 1S10 OD018130 (FTC).
Author details
1Molecular Imaging Program at Stanford (MIPS) Department of Radiology
Stanford University, Stanford, CA 94305, USA. 2Department of Neurology and
Neurological Sciences, Stanford University, Stanford, CA 94305, USA.
3Department of Chemistry and Biochemistry, University of California Santa
Barbara, Santa Barbara, CA 93106, USA. 4Department of Medicinal Chemistry
and Pharmacology, The University of Mississippi, University, MS 38677, USA.
5Veterans Administration Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Received: 5 June 2015 Accepted: 11 August 2015
References
1. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD.
Rat-liver and kidney contain high-densities of sigma(1) and sigma(2)
receptors - characterization by ligand-binding and photoaffinity-labeling.
Eur J Pharm Molec Ph. 1994;268:9–18.
2. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of
neuropsychiatric disorders. CNS Drugs. 2004;18:269–84.
3. Fishback JA, Robson MJ, Xu YT, Matsumoto RR. Sigma receptors: potential
targets for a new class of antidepressant drug. Pharmacol Ther.
2010;127(3):271–82.
4. Maurice T. Improving Alzheimer’s disease-related cognitive deficits with
sigma 1 receptor agonists. Drug News Perspect. 2002;15(10):617–25.
5. Nieto FR, Cendán CM, Sánchez-Fernández C, Cobos EJ, Entrena JM,
Tejada MA, et al. Role of sigma-1 receptors in paclitaxel-induced
neuropathic pain in mice. J Pain. 2012;13(11):1107–21.
6. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-Mitochondrion
interface regulate Ca2+ signaling and cell survival. Cell. 2007;131:596–610.
7. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor
chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci.
2010;31:557–66.
8. Banister SD, Kassiou M. The therapeutic potential of sigma (sigma) receptors
for the treatment of central nervous system diseases: evaluation of the
evidence. Curr Pharm Design. 2012;18:884–901.9. Bhuiyan MDS, Fukunaga K. Targeting sigma-1 receptor signaling by
endogenous ligands for cardioprotection. Expert Opin Ther Tar.
2011;15:145–55.
10. van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH,
Dierckx RAJO. Sigma receptors in oncology: therapeutic and diagnostic
applications of sigma ligands. Curr Pharm Design. 2010;16:3519–37.
11. Banister SD, Manoli M, Kassiou M. The development of radiotracers for
imaging sigma (sigma) receptors in the central nervous system (CNS)
using positron emission tomography (PET). J Labelled Compd Rad.
2013;56:215–24.
12. Lever JR, Gustafson JL, Xu R, Allmon RL, Lever SZ. Sigma(1) and sigma(2)
receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503.
Synapse. 2006;59:350–8.
13. Toyohara J, Sakata M, Ishiwata K. Imaging of sigma1 receptors in the human
brain using PET and [11C]SA4503. Cent Nerv Syst Agents Med Chem.
2009;9(3):190–6.
14. Ishiwata K, Kawamura K, Yajima K, Tu QGL, Mori H, Shiba K. Evaluation of
(+)-p-[C-11]methylvesamicol for mapping sigma(1) receptors: a comparison
with [C-11]SA4503. Nucl Med Biol. 2006;33:543–8.
15. Waterhouse RN, Zhao J, Stabin MG, Ng H, Schindler-Horvat J, et al.
Preclinical acute toxicity studies and dosimetry estimates of the novel
sigma-1 receptor radiotracer, [18F]SFE. Mol Imaging Biol. 2006;8(5):284–91.
16. Brust P, Deuther-Conrad W, Becker G, Patt M, Donat CK, et al. Distinctive
in vivo kinetics of the New σ1 receptor ligands (R)-(1)- and (S)-(−)-18F-
fluspidine in porcine brain. J Nucl Med. 2014;55:1730–6.
17. Waterhouse RN, Collier TL. In vivo evaluation of [F-18]1-(3-fluoropropyl)-
4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor
radioligand for PET. Nucl Med Biol. 1997;24:127–34.
18. Fischer S, Wiese C, Maestrup EG, Hiller A, Deuther-Conrad W, Scheunemann M,
et al. Molecular imaging of σ receptors: synthesis and evaluation of the potent
σ1 selective radioligand [18F]fluspidine. Eur J Nucl Med Mol Imaging.
2011;38:540–51.
19. James ML, Shen B, Zavaleta CL, Nielsen CH, Mesangeau C, Vuppala PK, et al.
New Positron Emission Tomography (PET) radioligand for imaging sigma-1
receptors in living subjects. J Med Chem. 2012;55:8272–82.
20. James ML, Shen B, Nielsen CH, Behera D, Buckmaster CL, Mesangeau C,
et al. Evaluation of sigma-1 receptor radioligand F-18-FTC-146 in rats and
squirrel monkeys using PET. J Nucl Med. 2014;55:147–53.
21. Tu ZD, Wang W, Cui JQ, Zhang X, Lu XX, Xu JB, et al. Synthesis and
evaluation of in vitro bioactivity for vesicular acetylcholine transporter
inhibitors containing two carbonyl groups. Bioorg Med Chem.
2012;20:4422–9.
22. Weissman AD, Su TP, Hedreen JC, London ED. Sigma receptors in
post-mortem human brains. J Pharmacol Exp Ther. 1988;247:29–33.
23. Mavlyutov TA, Epstein ML, Liu P, Verbney YI, Ziskind-Conhaim L, Ruoho AE.
Development of the sigma-1 receptor in C-terminals of motoneurons and
colocalization with the N, N’-dimethyltryptamine forming enzyme, indole-N-
methyl transferase. Neuroscience. 2012;206:68–80.
24. Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, et al. In vivo
evaluation of [C-11]SA4503 as a PET ligand for mapping CNS sigma(1)
receptors. Nucl Med Biol. 2000;27:255–61.
25. Ehmke H. The sigma-1 receptor: a molecular chaperone for the heart and
the soul? Cardiovasc Res. 2012;93:6–7.
26. Fujita T, Majikawa Y, Umehisa S, Okada N, Yamamoto A. Sigma receptor ligand-
induced up-regulation of the H+/peptide transporter PEPT1 in the human
intestinal cell line caco-2. Biochem Biophys Res Commun. 1999;261:242–6.
27. Hayashi T, Su T-P. The sigma receptor: evolution of the concept in
neuropsychopharmacology. Curr Neuropharmacol. 2005;3:267–80.
28. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are
expressed in a wide variety of human and rodent tumor cell lines.
Cancer Res. 1995;55:408–13.
29. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic
potential. Psychopharmacology. 2004;174:301–19.
30. Brust P, Deuther-Conrad W, Lehmkuhl K, Jia H, Wunsch B. Molecular
imaging of σ1 receptors in vivo: current status and perspectives. Curr Med
Chem. 2014;21:35–69.
